Publications by authors named "David Schaer"

Claim this Profile
T
Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.
Yanxia Li, Nelusha Amaladas, Marguerita O'Mahony, Jason R Manro, Ivan Inigo, David A Schaer

PLoS One· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Evaluation of Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy.
Kevin P Maresca, Jianqing Chen, Divya Mathur, Anand Giddabasappa, Adam Root, David Schaer

Mol Imaging Biol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study.
Karen A Autio, Christopher A Klebanoff, David Schaer, John Sae Wook Kauh, Susan F Slovin

Clin Cancer Res· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy.
David A Schaer, Sandaruwan Geeganage, Nelusha Amaladas, Zhao Hai Lu, Erik R Rasmussen

Clin Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational design of anti-GITR-based combination immunotherapy.
Roberta Zappasodi, Cynthia Sirard, Yanyun Li, Sadna Budhu, Mohsen Abu-Akeel, David Schaer

Nat Med· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety.
Nada S Alakhras, Jiabin Qiu, Guilherme V Rocha, Derrick R Witcher, Anja Koester, David A Schaer

MAbs· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.
Randi B Gombos, Ana Gonzalez, Mariana Manrique, Dhan Chand, David Savitsky, David Schaer

PLoS One· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
Rikke B Holmgaard, David A Schaer, Yanxia Li, Stephen P Castaneda, Mary Y Murphy

J Immunother Cancer· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.
David A Schaer, Richard P Beckmann, Jack A Dempsey, Lysiane Huber, Amelie Forest

Cell Rep· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment.
Sadna Budhu, David A Schaer, Yongbiao Li, Ricardo Toledo-Crow, Katherine Panageas

Sci Signal· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.
Rikke B Holmgaard, Alexandra Brachfeld, Billel Gasmi, David R Jones, Marissa Mattar, David Schaer

Oncoimmunology· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy.
David A Schaer, Daniel Hirschhorn-Cymerman, Jedd D Wolchok

J Immunother Cancer· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.
David A Schaer, Sadna Budhu, Cailian Liu, Campbell Bryson, Nicole Malandro

Cancer Immunol Res· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types.
Paolo A Ascierto, Michael Kalos, David A Schaer, Margaret K Callahan, Jedd D Wolchok

Clin Cancer Res· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of GITR for cancer immunotherapy.
David A Schaer, Judith T Murphy, Jedd D Wolchok

Curr Opin Immunol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope.
David A Schaer, Yongbiao Li, Taha Merghoub, Gabrielle A Rizzuto, Amos Shemesh

PLoS One· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hiding the road signs that lead to tumor immunity.
David A Schaer, Alexander M Lesokhin, Jedd D Wolchok

J Exp Med· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma.
Miriam Benezra, Oula Penate-Medina, Pat B Zanzonico, David Schaer, Hooisweng Ow

J Clin Invest· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of CTLA-4 and GITR for cancer immunotherapy.
Francesca Avogadri, Jianda Yuan, Arvin Yang, David Schaer, Jedd D Wolchok

Curr Top Microbiol Immunol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-GITR antibodies--potential clinical applications for tumor immunotherapy.
David A Schaer, Adam D Cohen, Jedd D Wolchok

Curr Opin Investig Drugs· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Adam D Cohen, David A Schaer, Cailian Liu, Yanyun Li, Daniel Hirschhorn-Cymmerman

PLoS One· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defective adhesion in tumor infiltrating CD8+ T cells.
Mythili Koneru, Ngozi Monu, David Schaer, Justine Barletta, Alan B Frey

J Immunol· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function.
Mythili Koneru, David Schaer, Ngozi Monu, Aidee Ayala, Alan B Frey

J Immunol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis